LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,149
تعداد مقالات10,518
تعداد مشاهده مقاله45,422,849
تعداد دریافت فایل اصل مقاله11,296,512
Yarahmadi, Pourya, Alirezaei, Mohammad, Forouzannia, Seyed Mohammad, Naser Moghadasi, Abdorreza. (1400). The Outcome of COVID-19 in Patients with a History of Taking Rituximab: A Narrative Review. سامانه مدیریت نشریات علمی, 46(6), 411-419. doi: 10.30476/ijms.2021.88717.1946
Pourya Yarahmadi; Mohammad Alirezaei; Seyed Mohammad Forouzannia; Abdorreza Naser Moghadasi. "The Outcome of COVID-19 in Patients with a History of Taking Rituximab: A Narrative Review". سامانه مدیریت نشریات علمی, 46, 6, 1400, 411-419. doi: 10.30476/ijms.2021.88717.1946
Yarahmadi, Pourya, Alirezaei, Mohammad, Forouzannia, Seyed Mohammad, Naser Moghadasi, Abdorreza. (1400). 'The Outcome of COVID-19 in Patients with a History of Taking Rituximab: A Narrative Review', سامانه مدیریت نشریات علمی, 46(6), pp. 411-419. doi: 10.30476/ijms.2021.88717.1946
Yarahmadi, Pourya, Alirezaei, Mohammad, Forouzannia, Seyed Mohammad, Naser Moghadasi, Abdorreza. The Outcome of COVID-19 in Patients with a History of Taking Rituximab: A Narrative Review. سامانه مدیریت نشریات علمی, 1400; 46(6): 411-419. doi: 10.30476/ijms.2021.88717.1946

The Outcome of COVID-19 in Patients with a History of Taking Rituximab: A Narrative Review

Iranian Journal of Medical Sciences
مقاله 1، دوره 46، شماره 6، بهمن 2021، صفحه 411-419    اصل مقاله (272.49 K)
نوع مقاله: Review Article
شناسه دیجیتال (DOI): 10.30476/ijms.2021.88717.1946
نویسندگان
Pourya Yarahmadi؛ Mohammad Alirezaei؛ Seyed Mohammad Forouzannia؛ Abdorreza Naser Moghadasi*
Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
چکیده
Coronavirus disease 2019 (COVID-19) is a recently emerging disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Notably, the safety of immunosuppressive medications is a major concern during an infectious disease pandemic. Rituximab (RTX), as a monoclonal antibody against CD20 molecule, is widely used for the treatment of various diseases, mostly autoimmune diseases and some malignancies. Previous studies indicated that RTX, as an immunosuppressive medication, may be associated with the increased risk of infections. Moreover, given the wide use of RTX, a necessity of determining the different aspects of RTX use in the COVID-19 era is strongly felt. We reviewed current studies on the clinical courses of patients with SARS-CoV-2 infection. It appears that the use of RTX does not increase morbidity and mortality in most patients. However, underlying diseases and other concomitant medications may play a role in the disease course, while the concerns of vaccine efficacy in patients receiving RTX still need to be addressed. Therefore, more controlled studies are needed for a better conclusion.
کلیدواژه‌ها
Rituximab؛ COVID-19؛ SARS-CoV-2؛ Immune system diseases
سایر فایل های مرتبط با مقاله
مراجع
  1. Kordzadeh-Kermani E, Khalili H, Karimzadeh I. Pathogenesis, clinical manifestations and complications of coronavirus disease 2019 (COVID-19). Future Microbiol. 2020;15:1287-305. doi: 10.2217/fmb-2020-0110. PubMed PMID: 32851877; PubMed Central PMCID: PMCPMC7493723.
  2. Pascarella G, Strumia A, Piliego C, Bruno F, Del Buono R, Costa F, et al. COVID-19 diagnosis and management: a comprehensive review. J Intern Med. 2020;288:192-206. doi: 10.1111/joim.13091. PubMed PMID: 32348588; PubMed Central PMCID: PMCPMC7267177.
  3. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91-5. doi: 10.1016/j.ijid.2020.03.017. PubMed PMID: 32173574; PubMed Central PMCID: PMCPMC7194638.
  4. Freeman CL, Sehn LH. A tale of two antibodies: obinutuzumab versus rituximab. Br J Haematol. 2018;182:29-45. doi: 10.1111/bjh.15232. PubMed PMID: 29741753.
  5. Salles G, Barrett M, Foa R, Maurer J, O’Brien S, Valente N, et al. Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. Adv Ther. 2017;34:2232-73. doi: 10.1007/s12325-017-0612-x. PubMed PMID: 28983798; PubMed Central PMCID: PMCPMC5656728.
  6. Hu Y, Nie H, Yu HH, Qin C, Wu LJ, Tang ZP, et al. Efficacy and safety of rituximab for relapsing-remitting multiple sclerosis: A systematic review and meta-analysis. Autoimmun Rev. 2019;18:542-8. doi: 10.1016/j.autrev.2019.03.011. PubMed PMID: 30844555.
  7. Damato V, Evoli A, Iorio R. Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders: A Systematic Review and Meta-analysis. JAMA Neurol. 2016;73:1342-8. doi: 10.1001/jamaneurol.2016.1637. PubMed PMID: 27668357.
  8. Tandan R, Hehir MK, Waheed W, Howard DB. Rituximab treatment of myasthenia gravis: A systematic review. Muscle Nerve. 2017;56:185-96. doi: 10.1002/mus.25597. PubMed PMID: 28164324.
  9. Hassan RI, Gaffo AL. Rituximab in ANCA-Associated Vasculitis. Curr Rheumatol Rep. 2017;19:6. doi: 10.1007/s11926-017-0632-1. PubMed PMID: 28155022.
  10. Tavakolpour S, Alesaeidi S, Darvishi M, GhasemiAdl M, Darabi-Monadi S, Akhlaghdoust M, et al. A comprehensive review of rituximab therapy in rheumatoid arthritis patients. Clin Rheumatol. 2019;38:2977-94. doi: 10.1007/s10067-019-04699-8. PubMed PMID: 31367943.
  11. Elhai M, Boubaya M, Distler O, Smith V, Matucci-Cerinic M, Alegre Sancho JJ, et al. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Ann Rheum Dis. 2019;78:979-87. doi: 10.1136/annrheumdis-2018-214816. PubMed PMID: 30967395.
  12. Wang HH, Liu CW, Li YC, Huang YC. Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens. Acta Derm Venereol. 2015;95:928-32. doi: 10.2340/00015555-2116. PubMed PMID: 25881672.
  13. Li Y, Shi Y, He Z, Chen Q, Liu Z, Yu L, et al. The efficacy and safety of low-dose rituximab in immune thrombocytopenia: a systematic review and meta-analysis. Platelets. 2019;30:690-7. doi: 10.1080/09537104.2019.1624706. PubMed PMID: 31159633.
  14. Chauhan K, Mehta AA. Rituximab in kidney disease and transplant. Animal Model Exp Med. 2019;2:76-82. doi: 10.1002/ame2.12064. PubMed PMID: 31392300; PubMed Central PMCID: PMCPMC6600632.
  15. Barmettler S, Ong MS, Farmer JR, Choi H, Walter J. Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia. JAMA Netw Open. 2018;1:e184169. doi: 10.1001/jamanetworkopen.2018.4169. PubMed PMID: 30646343; PubMed Central PMCID: PMCPMC6324375.
  16. Aksoy S, Dizdar O, Hayran M, Harputluoglu H. Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis. Leuk Lymphoma. 2009;50:357-65. doi: 10.1080/10428190902730219. PubMed PMID: 19263297.
  17. Shi Y, Wu Y, Ren Y, Jiang Y, Chen Y. Infection risks of rituximab versus non-rituximab treatment for rheumatoid arthritis: A systematic review and meta-analysis. Int J Rheum Dis. 2019;22:1361-70. doi: 10.1111/1756-185X.13596. PubMed PMID: 31099191.
  18. Montero-Escribano P, Matias-Guiu J, Gomez-Iglesias P, Porta-Etessam J, Pytel V, Matias-Guiu JA. Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: A case series of 60 patients from Madrid, Spain. Mult Scler Relat Disord. 2020;42:102185. doi: 10.1016/j.msard.2020.102185. PubMed PMID: 32408147; PubMed Central PMCID: PMCPMC7204643.
  19. Woo MS, Steins D, Haussler V, Kohsar M, Haag F, Elias-Hamp B, et al. Control of SARS-CoV-2 infection in rituximab-treated neuroimmunological patients. J Neurol. 2021;268:5-7. doi: 10.1007/s00415-020-10046-8. PubMed PMID: 32654064; PubMed Central PMCID: PMCPMC7353821.
  20. Louapre C, Maillart E, Papeix C, Zeidan S, Biotti D, Lepine Z, et al. Outcomes of coronavirus disease 2019 in patients with neuromyelitis optica and associated disorders. Eur J Neurol. 2020. doi: 10.1111/ene.14612. PubMed PMID: 33103295.
  21. Sahraian MA, Azimi A, Navardi S, Rezaeimanesh N, Naser Moghadasi A. Evaluation of COVID-19 infection in patients with Neuromyelitis optica spectrum disorder (NMOSD): A report from Iran. Mult Scler Relat Disord. 2020;44:102245. doi: 10.1016/j.msard.2020.102245. PubMed PMID: 32512287; PubMed Central PMCID: PMCPMC7832017.
  22. Devogelaere J, D’Hooghe M B, Vanderhauwaert F, D’Haeseleer M. Coronavirus disease 2019: favorable outcome in an immunosuppressed patient with multiple sclerosis. Neurol Sci. 2020;41:1981-3. doi: 10.1007/s10072-020-04522-2. PubMed PMID: 32564270; PubMed Central PMCID: PMCPMC7305693.
  23. Creed MA, Ballesteros E, Jr LJG, Imitola J. Mild COVID-19 infection despite chronic B cell depletion in a patient with aquaporin-4-positive neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2020;44:102199. doi: 10.1016/j.msard.2020.102199. PubMed PMID: 32554285; PubMed Central PMCID: PMCPMC7236713.
  24. Wurm H, Attfield K, Iversen AK, Gold R, Fugger L, Haghikia A. Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient. Mult Scler. 2020;26:1261-4. doi: 10.1177/1352458520943791. PubMed PMID: 32762494; PubMed Central PMCID: PMCPMC7502978.
  25. Meca-Lallana V, Aguirre C, Beatrizdel R, Cardenoso L, Alarcon T, Vivancos J. COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies. Mult Scler Relat Disord. 2020;44:102306. doi: 10.1016/j.msard.2020.102306. PubMed PMID: 32585617; PubMed Central PMCID: PMCPMC7295509.
  26. Safavi F, Nourbakhsh B, Azimi AR. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran. Mult Scler Relat Disord. 2020;43:102195. doi: 10.1016/j.msard.2020.102195. PubMed PMID: 32460086; PubMed Central PMCID: PMCPMC7219389.
  27. Parrotta E, Kister I, Charvet L, Sammarco C, Saha V, Charlson RE, et al. COVID-19 outcomes in MS: Observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center. Neurol Neuroimmunol Neuroinflamm. 2020;7. doi: 10.1212/NXI.0000000000000835. PubMed PMID: 32646885; PubMed Central PMCID: PMCPMC7357412.
  28. Wanschitz JV, Kaml M, Pfausler B, Helbok R, Wildner S, Widmann G, et al. Myasthenic crisis following SARS-CoV-2 infection and delayed virus clearance in a patient treated with rituximab: clinical course and 6-month follow-up. J Neurol. 2021;268:2700-2. doi: 10.1007/s00415-020-10310-x. PubMed PMID: 33216224; PubMed Central PMCID: PMCPMC7678580.
  29. Guilpain P, Le Bihan C, Foulongne V, Taourel P, Pansu N, Maria ATJ, et al. Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia. Ann Rheum Dis. 2021;80:e10. doi: 10.1136/annrheumdis-2020-217549. PubMed PMID: 32312768.
  30. Sharmeen S, Elghawy A, Zarlasht F, Yao Q. COVID-19 in rheumatic disease patients on immunosuppressive agents. Semin Arthritis Rheum. 2020;50:680-6. doi: 10.1016/j.semarthrit.2020.05.010. PubMed PMID: 32512263; PubMed Central PMCID: PMCPMC7245236.
  31. Fallet B, Kyburz D, Walker UA. Mild Course of COVID-19 and Spontaneous Virus Clearance in a Patient With Depleted Peripheral Blood B Cells Due to Rituximab Treatment. Arthritis Rheumatol. 2020;72:1581-2. doi: 10.1002/art.41380. PubMed PMID: 32458534; PubMed Central PMCID: PMCPMC7283641.
  32. Loarce-Martos J, Garcia-Fernandez A, Lopez-Gutierrez F, Garcia-Garcia V, Calvo-Sanz L, Del Bosque-Granero I, et al. High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study. Rheumatol Int. 2020;40:2015-21. doi: 10.1007/s00296-020-04699-x. PubMed PMID: 32945944; PubMed Central PMCID: PMCPMC7499013.
  33. Schulze-Koops H, Krueger K, Vallbracht I, Hasseli R, Skapenko A. Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab. Ann Rheum Dis. 2020. doi: 10.1136/annrheumdis-2020-218075. PubMed PMID: 32591357; PubMed Central PMCID: PMCPMC7371570.
  34. Avouac J, Airo P, Carlier N, Matucci-Cerinic M, Allanore Y. Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab. Ann Rheum Dis. 2020. doi: 10.1136/annrheumdis-2020-217864. PubMed PMID: 32503849.
  35. Daneshpazhooh M, Soori T, Isazade A, Noormohammadpour P. Mucous membrane pemphigoid and COVID-19 treated with high-dose intravenous immunoglobulins: a case report. J Dermatolog Treat. 2020;31:446-7. doi: 10.1080/09546634.2020.1764472. PubMed PMID: 32363963.
  36. Shahidi-Dadras M, Abdollahimajd F, Ohadi L, Tabary M, Araghi F, Mozafari N, et al. COVID-19 in pemphigus vulgaris patients with previous rituximab therapy: a tele-medicine experience. J Dermatolog Treat. 2020:1-2. doi: 10.1080/09546634.2020.1789041. PubMed PMID: 32594787.
  37. Furstenau M, Langerbeins P, De Silva N, Fink AM, Robrecht S, von Tresckow J, et al. COVID-19 among fit patients with CLL treated with venetoclax-based combinations. Leukemia. 2020;34:2225-9. doi: 10.1038/s41375-020-0941-7. PubMed PMID: 32601378; PubMed Central PMCID: PMCPMC7323604.
  38. Li Q, Zhu F, Xiao Y, Liu T, Liu X, Wu G, et al. A Primary Mediastinal Large B-Cell Lymphoma Patient With COVID-19 Infection After Intensive Immunochemotherapy: A Case Report. Front Oncol. 2020;10:924. doi: 10.3389/fonc.2020.00924. PubMed PMID: 32574278; PubMed Central PMCID: PMCPMC7256193.
  39. Tepasse PR, Hafezi W, Lutz M, Kuhn J, Wilms C, Wiewrodt R, et al. Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature. Br J Haematol. 2020;190:185-8. doi: 10.1111/bjh.16896. PubMed PMID: 32557623; PubMed Central PMCID: PMCPMC7300950.
  40. Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. 2020;14:185-92. doi: 10.1007/s11684-020-0754-0. PubMed PMID: 32170560; PubMed Central PMCID: PMCPMC7088738.
  41. Garcia LF. Immune Response, Inflammation, and the Clinical Spectrum of COVID-19. Front Immunol. 2020;11:1441. doi: 10.3389/fimmu.2020.01441. PubMed PMID: 32612615; PubMed Central PMCID: PMCPMC7308593.
  42. Kellam P, Barclay W. The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection. J Gen Virol. 2020;101:791-7. doi: 10.1099/jgv.0.001439. PubMed PMID: 32430094; PubMed Central PMCID: PMCPMC7641391.
  43. Quinti I, Lougaris V, Milito C, Cinetto F, Pecoraro A, Mezzaroma I, et al. A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia. J Allergy Clin Immunol. 2020;146:211-3 e4. doi: 10.1016/j.jaci.2020.04.013. PubMed PMID: 32333914; PubMed Central PMCID: PMCPMC7175894.
  44. Novi G, Mikulska M, Briano F, Toscanini F, Tazza F, Uccelli A, et al. COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role? Mult Scler Relat Disord. 2020;42:102120. doi: 10.1016/j.msard.2020.102120. PubMed PMID: 32315980; PubMed Central PMCID: PMCPMC7156942.
  45. Suwanwongse K, Shabarek N. Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab. Mult Scler Relat Disord. 2020;42:102201. doi: 10.1016/j.msard.2020.102201. PubMed PMID: 32480327; PubMed Central PMCID: PMCPMC7227515.
  46. Hughes R, Pedotti R, Koendgen H. COVID-19 in persons with multiple sclerosis treated with ocrelizumab - A pharmacovigilance case series. Mult Scler Relat Disord. 2020;42:102192. doi: 10.1016/j.msard.2020.102192. PubMed PMID: 32570202; PubMed Central PMCID: PMCPMC7228884.
  47. Ghajarzadeh M, Mirmosayyeb O, Barzegar M, Nehzat N, Vaheb S, Shaygannejad V, et al. Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic. Mult Scler Relat Disord. 2020;43:102222. doi: 10.1016/j.msard.2020.102222. PubMed PMID: 32464586; PubMed Central PMCID: PMCPMC7245286.
  48. Kordzadeh-Kermani E, Khalili H, Karimzadeh I, Salehi M. Prevention Strategies to Minimize the Infection Risk Associated with Biologic and Targeted Immunomodulators. Infect Drug Resist. 2020;13:513-32. doi: 10.2147/IDR.S233137. PubMed PMID: 32110062; PubMed Central PMCID: PMCPMC7035951.
  49. Nazi I, Kelton JG, Larche M, Snider DP, Heddle NM, Crowther MA, et al. The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood. 2013;122:1946-53. doi: 10.1182/blood-2013-04-494096. PubMed PMID: 23851398; PubMed Central PMCID: PMCPMC3773242.
  50. Cheng DR, Barton R, Greenway A, Crawford NW. Rituximab and protection from vaccine preventable diseases: applying the evidence to pediatric patients. Expert Rev Vaccines. 2016;15:1567-74. doi: 10.1080/14760584.2016.1193438. PubMed PMID: 27216827.
  51. Kim W, Kim SH, Huh SY, Kong SY, Choi YJ, Cheong HJ, et al. Reduced antibody formation after influenza vaccination in patients with neuromyelitis optica spectrum disorder treated with rituximab. Eur J Neurol. 2013;20:975-80. doi: 10.1111/ene.12132. PubMed PMID: 23521577.
  52. Bingham CO, Looney RJ, Deodhar A, Halsey N, Greenwald M, Codding C, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum. 2010;62:64-74. doi: 10.1002/art.25034. PubMed PMID: 20039397.
  53. Friedman MA, Winthrop KL. Vaccines and Disease-Modifying Antirheumatic Drugs: Practical Implications for the Rheumatologist. Rheum Dis Clin North Am. 2017;43:1-13. doi: 10.1016/j.rdc.2016.09.003. PubMed PMID: 27890167.
  54. Lucchini M, Bianco A, Del Giacomo P, De Fino C, Nociti V, Mirabella M. Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report. Mult Scler Relat Disord. 2020;44:102323. doi: 10.1016/j.msard.2020.102323. PubMed PMID: 32593961; PubMed Central PMCID: PMCPMC7307994.
  55. Thornton JR, Harel A. Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumab. Mult Scler Relat Disord. 2020;44:102341. doi: 10.1016/j.msard.2020.102341. PubMed PMID: 32622338; PubMed Central PMCID: PMCPMC7318946.
  56. Conte WL. Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia. Mult Scler Relat Disord. 2020;44:102315. doi: 10.1016/j.msard.2020.102315. PubMed PMID: 32593144; PubMed Central PMCID: PMCPMC7305883.
  57. Benetti F, Del Prete SH, Glanc M, Navia D. COVID-19: An Argentinian perspective. J Card Surg. 2021;36:1717-22. doi: 10.1111/jocs.15235. PubMed PMID: 33491254; PubMed Central PMCID: PMCPMC8013803.
  58. Li L, Xv Q, Yan J. COVID-19: the need for continuous medical education and training. Lancet Respir Med. 2020;8:e23. doi: 10.1016/S2213-2600(20)30125-9. PubMed PMID: 32192586; PubMed Central PMCID: PMCPMC7104229.
  59. Ferro F, Elefante E, Baldini C, Bartoloni E, Puxeddu I, Talarico R, et al. COVID-19: the new challenge for rheumatologists. Clin Exp Rheumatol. 2020;38:175-80. PubMed PMID: 32207680.
  60. Ferro F, Elefante E, Puxeddu I, Baldini C, Bartoloni E, Barate C, et al. COVID-19: the new challenge for rheumatologists. First update. Clin Exp Rheumatol. 2020;38:373-82. PubMed PMID: 32452355.
  61. Graf J, Mares J, Barnett M, Aktas O, Albrecht P, Zamvil SS, et al. Targeting B Cells to Modify MS, NMOSD, and MOGAD: Part 1. Neurol Neuroimmunol Neuroinflamm. 2021;8. doi: 10.1212/NXI.0000000000000918. PubMed PMID: 33406479; PubMed Central PMCID: PMCPMC8063619.
  62. Lytvyn Y, Rahat S, Mufti A, Witol A, Bagit A, Sachdeva M, et al. Biologic treatment outcomes in mucous membrane pemphigoid: A systematic review. J Am Acad Dermatol. 2021. doi: 10.1016/j.jaad.2020.12.056. PubMed PMID: 33422625.
  63. Lee WS, Amengual O. B cells targeting therapy in the management of systemic lupus erythematosus. Immunol Med. 2020;43:16-35. doi: 10.1080/25785826.2019.1698929. PubMed PMID: 32107989.
  64. Moghadasi AN. Should Patients with MS Discontinue Their Medications During the COVID-19 Pandemic? Arch Neurosci. 2020;7:e103409. doi: 10.5812/ans.103409.
آمار
تعداد مشاهده مقاله: 4,360
تعداد دریافت فایل اصل مقاله: 3,051


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب